Liraglutide
Liraglutide (marketed with brand name Victoza) is a Type 2 diabetes medication. It is a long-acting glucagon like peptide-1 agonist. It was approved by the Food and Drug Administration in early 2010.
![]() NMR structure of liraglutide. PDB entry 4apd | |
Clinical data | |
---|---|
Trade names | Victoza, Saxenda |
License data | |
Pregnancy category |
|
Routes of administration | subcutaneous |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
ECHA InfoCard | 100.241.015 |
Chemical and physical data | |
Formula | C172H265N43O51 |
Molar mass | 3751.202 g/mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
This medication is a once daily treatment of Type 2 diabetes.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.